Accepted for/Published in: JMIR Research Protocols
Date Submitted: Feb 25, 2023
Date Accepted: Jul 19, 2023
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Better Night, Better Days for Children with Neurodevelopmental Disorders eHealth program: Protocol for an Economic Evaluation of a Randomized Controlled Trial
ABSTRACT
Background:
Children with neurodevelopmental disorders have a high risk of sleep disturbances, with insomnia being the most common sleep disorder (i.e., chronic and frequent difficulties with going and staying asleep). Insomnia adversely affects the well-being of these children and their caregivers. Pediatric sleep experts recommend behavioral interventions as the first-line treatment option for children. Better Nights, Better Days for Children with Neurodevelopmental Disorders (BNBD-NDD) is a five-session eHealth behavioural intervention delivered to parents to improve outcomes (e.g., Pediatric Quality of Life Inventory) for their children (4-12 years) with insomnia and who have a diagnosis of mild-to-moderate attention-deficit/hyperactivity disorder, autism spectrum disorder, cerebral palsy, and/or fetal alcohol spectrum disorder. If effective, BNBD-NDD can be a scalable intervention that provides value to an underserved population.
Objective:
This protocol outlines an economic evaluation conducted alongside the BNBD-NDD randomized controlled trial (RCT) that aims to assess its costs and effectiveness compared to usual care.
Methods:
The BNBD-NDD RCT evaluates the impacts of the intervention on children’s sleep and quality of life, as well as parent daytime functioning and psychosocial health. Parent participants were randomized to the BNBD-NDD treatment or to usual care. The economic evaluation assesses outcomes at baseline and 8 months later, which include the Pediatric Quality of Life Inventory (PedsQL) as the primary measure. Quality of life outcomes facilitates the comparison of competing interventions across different populations and medical conditions. Cost items include the BNBD-NDD intervention and parent-reported utilization of private and publicly funded resources for their children’s insomnia. The economic evaluation involves a reference-case cost-effectiveness analysis to examine the incremental cost of BNBD-NDD per unit(s) gain in the PedsQL from the family payer perspective and a cost-consequence analysis from a societal perspective. These analyses will be conducted over an 8-month time horizon.
Results:
The BNBD-NDD RCT data collection commenced in June 2019 and ended in April 2022. The RCT data are currently being analyzed, and data relevant to the economic analysis will be analyzed concurrently.
Conclusions:
To our knowledge, this will be the first economic evaluation of an eHealth intervention for insomnia in children with neurodevelopmental disorders. This evaluation's findings can inform users and stakeholders regarding the costs and benefits of BNBD-NDD. Clinical Trial: ClinicalTrial.gov ID NCT02694003
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.